iShares Nasdaq Biotechnology ETF (IBB) is Blume Capital Management Inc.’s 5th Largest Position

Blume Capital Management Inc. lowered its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,493 shares of the financial services provider’s stock after selling 1,495 shares during the period. iShares Nasdaq Biotechnology ETF accounts for 3.6% of Blume Capital Management Inc.’s portfolio, making the stock its 5th largest holding. Blume Capital Management Inc. owned 0.09% of iShares Nasdaq Biotechnology ETF worth $6,316,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in IBB. Broadleaf Partners LLC boosted its position in iShares Nasdaq Biotechnology ETF by 4.0% during the fourth quarter. Broadleaf Partners LLC now owns 2,459 shares of the financial services provider’s stock worth $237,000 after purchasing an additional 95 shares during the period. F&V Capital Management LLC boosted its position in iShares Nasdaq Biotechnology ETF by 1.8% during the fourth quarter. F&V Capital Management LLC now owns 5,593 shares of the financial services provider’s stock worth $539,000 after purchasing an additional 100 shares during the period. PFG Advisors boosted its position in iShares Nasdaq Biotechnology ETF by 4.8% during the fourth quarter. PFG Advisors now owns 2,723 shares of the financial services provider’s stock worth $293,000 after purchasing an additional 125 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its position in iShares Nasdaq Biotechnology ETF by 0.8% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 16,998 shares of the financial services provider’s stock worth $1,639,000 after purchasing an additional 134 shares during the period. Finally, Westside Investment Management Inc. boosted its position in iShares Nasdaq Biotechnology ETF by 3.4% during the fourth quarter. Westside Investment Management Inc. now owns 5,015 shares of the financial services provider’s stock worth $484,000 after purchasing an additional 165 shares during the period. Hedge funds and other institutional investors own 66.51% of the company’s stock.

Shares of iShares Nasdaq Biotechnology ETF stock opened at $108.34 on Tuesday. iShares Nasdaq Biotechnology ETF has a 12-month low of $89.01 and a 12-month high of $122.97.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/02/12/ishares-nasdaq-biotechnology-etf-ibb-is-blume-capital-management-inc-s-5th-largest-position.html.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply